ID: ALA5196183

Max Phase: Preclinical

Molecular Formula: C19H25N3O3S2

Molecular Weight: 407.56

Representations

Canonical SMILES:  Cc1cn(C)c(SCC2CCN(S(=O)(=O)c3ccc4c(c3)CCO4)CC2)n1

Standard InChI:  InChI=1S/C19H25N3O3S2/c1-14-12-21(2)19(20-14)26-13-15-5-8-22(9-6-15)27(23,24)17-3-4-18-16(11-17)7-10-25-18/h3-4,11-12,15H,5-10,13H2,1-2H3

Standard InChI Key:  NBAJUUMIEBLYEE-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 407.56

Molecular Weight (Monoisotopic): 407.1337

AlogP: 2.86

#Rotatable Bonds: 5

Polar Surface Area: 64.43

Molecular Species: NEUTRAL

HBA: 6

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 4.91

CX LogP: 2.62

CX LogD: 2.62

Aromatic Rings: 2

Heavy Atoms: 27

QED Weighted: 0.71

Np Likeness Score: -1.70

References

1. Garrison AT, Orsi DL, Capstick RA, Whomble D, Li J, Carter TR, Felts AS, Vinson PN, Rodriguez AL, Han A, Hajari K, Cho HP, Teal LB, Ragland MG, Ghamari-Langroudi M, Bubser M, Chang S, Schnetz-Boutaud NC, Boutaud O, Blobaum AL, Foster DJ, Niswender CM, Conn PJ, Lindsley CW, Jones CK, Han C..  (2022)  Development of VU6019650: A Potent, Highly Selective, and Systemically Active Orthosteric Antagonist of the M₅ Muscarinic Acetylcholine Receptor for the Treatment of Opioid Use Disorder.,  65  (8.0): [PMID:35417155] [10.1021/acs.jmedchem.2c00192]

Source

Source(1):

• Scientific Literature